(4R)-4-叠氮-1-BOC-D-脯氨酸苄酯,(4R)-4-AZIDO-1-BOC-D-PROLINEBENZYLESTER | 132622-97-0

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 脯氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (4R)-4-叠氮-1-BOC-D-脯氨酸苄酯,(4R)-4-AZIDO-1-BOC-D-PROLINEBENZYLESTER
• 英文名称: (4R)-1-(tert-butoxycarbonyl)-4-azido-D-proline benzyl ester
• 英文别名: (2R,4R)-1-(tert-butoxycarbonyl)-4-azidoproline benzyl ester；(2R,4R)-2-benzyl 1-tert-butyl 4-azidopyrrolidine-1,2-dicarboxylate；2-benzyl 1-(tert-butyl) (2R,4R)-4-azidopyrrolidine-1,2-dicarboxylate；(4R)-4-Azido-1-Boc-D-proline benzyl ester；2-O-benzyl 1-O-tert-butyl (2R,4R)-4-azidopyrrolidine-1,2-dicarboxylate
• CAS: 132622-97-0
• 化学式: C₁₇H₂₂N₄O₄
• 分子量: 346.386
• InChiKey: NNBVAZYHYUBQCU-ZIAGYGMSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  70.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (4R)-4-叠氮-1-BOC-D-脯氨酸苄酯,(4R)-4-AZIDO-1-BOC-D-PROLINEBENZYLESTER 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 反应 24.0h， 以3 g的产率得到1-N-boc-4(r)-氨基-吡咯烷-2(r)-羧酸
  参考文献：
  名称：

  [EN] INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
  [FR] INHIBITEURS DE LA KALLIKRÉINE PLASMATIQUE ET UTILISATIONS ASSOCIÉES

  摘要：

  本文提供了抑制pKal的化合物，pKal是一种丝氨酸蛋白酶，其活性负责蛋白酶解切激肽原并生成强效的血管舒张剂和促炎肽布雷金因，这可能导致疼痛和令人痛苦的炎症发作（例如水肿）。还提供了包含这些化合物的药物组合物和试剂盒，以及使用这些化合物在受试者中治疗pKal相关疾病和紊乱（例如水肿）的方法，通过给予本文所述的化合物和/或组合物。

  公开号：

  WO2019028362A1
• 作为产物：
  描述：

  (2R,4R)-4-羟基吡咯烷-2-羧酸苄酯 在 sodium azide 、 四溴化碳 、 N,N-二异丙基乙胺 、 三苯基膦 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 (4R)-4-叠氮-1-BOC-D-脯氨酸苄酯,(4R)-4-AZIDO-1-BOC-D-PROLINEBENZYLESTER
  参考文献：
  名称：

  Conformationally restricted arginine analogs

  摘要：

  We report the practical synthesis and structural characterization of a set of conformationally constrained protected arginine analogues. These enantiomerically pure analogues have the general structure 1 and are prepared in seven to eight steps from the commercially available isomers of 4-hydroxyproline. These analogues vary in side chain length and in relative and absolute stereochemistry and are suitable for the direct introduction into peptides. The resulting peptide analogues should be useful as enzymatically stable replacements for bioactive peptides and as probes for understanding the conformational aspects of protein-peptide interactions.

  DOI：

  10.1021/jo00009a016

文献信息

• [EN] ARGINASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE L'ARGINASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ASTRAZENECA AB

  公开号：WO2019159120A1

  公开（公告）日：2019-08-22

  Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase, wherein R1 is -NHR1a; R1a is -H or -C(O)CH(R1b)NHR1c; and R1b is selected from -H, -(C1-C4 ) alkyl and CH2OR1d and R1cis -H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or -CH3.

  化合物的结构式（Ia）或其药学上可接受的盐已被披露，包括化合物的结构式（Ia）的药物组合物以及使用它们用于治疗癌症或呼吸道炎症性疾病和抑制精氨酸酶的方法，其中R1为-NHR1a；R1a为-H或-C（O）CH（R1b）NHR1c；R1b从-H，-（C1-C4）烷基和CH2OR1d中选择，R1c为-H；或R1b和R1c与它们附着的原子一起形成5-成员杂环环；R1d为H或-CH3。
• [EN] INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF<br/>[FR] INHIBITEURS DE LA KALLIKRÉINE PLASMATIQUE ET UTILISATIONS ASSOCIÉES
  申请人：DYAX CORP

  公开号：WO2019028362A1

  公开（公告）日：2019-02-07

  Provided herein are compounds that inhibit pKal, a serine protease whose activity is responsible for proteolytically cleaving kininogen and generating the potent vasodilator and pro-inflammatory peptide bradykinin, which can lead to painful and debilitating inflammatory attacks (e.g., edema). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating pKal-related diseases and disorders (e.g., edema) with the compounds in a subject, by administering the compounds and/or compositions described herein.

  本文提供了抑制pKal的化合物，pKal是一种丝氨酸蛋白酶，其活性负责蛋白酶解切激肽原并生成强效的血管舒张剂和促炎肽布雷金因，这可能导致疼痛和令人痛苦的炎症发作（例如水肿）。还提供了包含这些化合物的药物组合物和试剂盒，以及使用这些化合物在受试者中治疗pKal相关疾病和紊乱（例如水肿）的方法，通过给予本文所述的化合物和/或组合物。
• Chimeric amino acid analogues
  申请人：Genentech, Inc.

  公开号：US05120859A1

  公开（公告）日：1992-06-09

  A chimeric amino acid analogue is provided suitable for incorporating into peptides which compound is represented by Formula 1: ##STR1## where P.sub.1 is preferably an amine protecting agent, and P.sub.2 and P.sub.3 are preferably amine or guanidine protecting agents. X can be OH, halide, or preferably an activating group suitable for conjugating the compound of Formula 1 to a peptide by conventional means, and m and n are 0-1 and 0-2 respectively. Peptides containing the chimeric amino acid analog are provided and include a platelet-aggregation inhibitor represented by Aaa.sub.1 -CPdl-Gly-Asp-Aaa.sub.2 where Aaa.sub.1 is Gly or H, Cpdl is the compound of Formula 1 which has been deprotected and Aaa.sub.2 is a hydrophobic amino acid preferably Val.

  提供了一种嵌入肽中的嵌合氨基酸类似物，该化合物由公式1表示：##STR1##其中，P.sub.1最好是氨基保护剂，P.sub.2和P.sub.3最好是氨基或鸟嘌呤保护剂。X可以是OH、卤素或更好的活化基团，适合通过常规手段将公式1化合物与肽结合，m和n分别为0-1和0-2。提供了含有嵌合氨基酸类似物的肽，其中包括一个由Aaa.sub.1-CPdl-Gly-Asp-Aaa.sub.2表示的血小板聚集抑制剂，其中Aaa.sub.1是Gly或H，Cpdl是已去保护的公式1化合物，Aaa.sub.2是一个亲水性氨基酸，最好是Val。
• Inhibitors of Plasma Kallikrein and uses thereof
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US11168083B2

  公开（公告）日：2021-11-09

  Provided herein are compounds that inhibit pKal, a serine protease whose activity is responsible for proteolytically cleaving kininogen and generating the potent vasodilator and pro-inflammatory peptide bradykinin, which can lead to painful and debilitating inflammatory attacks (e.g., edema). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating pKal-related diseases and disorders (e.g., edema) with the compounds in a subject, by administering the compounds and/or compositions described herein.

  本文提供了抑制 pKal 的化合物，pKal 是一种丝氨酸蛋白酶，其活性负责蛋白水解激肽原并生成强效血管扩张剂和促炎肽缓激肽，后者可导致疼痛和衰弱性炎症发作（如水肿）。此外，还提供了包含所述化合物的药物组合物和试剂盒，以及通过施用所述化合物和/或组合物在受试者体内用所述化合物治疗pKal相关疾病和失调（如水肿）的方法。
• WEBB, THOMAS R.;EIGENBROT, CHARLES, J. ORG. CHEM., 56,(1991) N, C. 3009-3016
  作者：WEBB, THOMAS R.、EIGENBROT, CHARLES

  DOI：——

  日期：——